摘要
目的：观察健脾化湿祛瘀解毒方对晚期大肠癌的治疗效果,并探讨其机理。
方法：选择晚期大肠癌患者30例,随机分为治疗组15例,服用健脾化湿祛瘀解毒方,并联合FOLFOX方案化疗；对照组15例,单纯予FOLFOX方案化疗。比较两组患者临床症状的缓解、治疗前后一般状况的改善、血清肿瘤标志物的变化及化疗不良反应的程度,进行量化评分作为疗效评价指标,并统计分析两组在上述指标方面的差异。
结果：治疗组的中医证候疗效有效率为86.67%,对照组有效率为60.00%,两组在统计学上有显著差异(P<0.05),说明治疗组在缓解临床症状方面的疗效明显优于对照组。两组患者治疗前的卡氏评分无统计学差异,但在治疗后两组的卡氏评分显示有统计学差异(P<0.05),说明治疗组在改善患者一般状况方面要优于对照组。CEA对大肠癌有一定的诊断意义,两组患者治疗前CEA值组间比较无显著性差异,在治疗后比较显示出有统计学差异,说明治疗组在降低CEA值方面较对照组也有一定优势。治疗组的肿瘤近期客观疗效有效率为33.33%,略好于对照组20.00%。两组比较无统计学差异(P>0.05)。
结论：健脾化湿祛瘀解毒方在晚期大肠癌的治疗中,具有改善临床症状和机体一般状况、减轻化疗副反应等作用,值得临床推广。
Object:To observe the clinic effect of Jian Pi Hua Shi Qu Yu Jie Du decoction in the treatment of advanced colorectal tumor.
Method:30 cases of advanced colorectal tumor were chosen and randomly divided into two groups,15 cases of trail group were treated with Jian Pi Hua Shi Qu Yu Jie Du decoction and chemotherapy with FOLFOX scheme another 15 cases of control group were treated with chemotherapy with the same scheme only.Compare the two groups in clinical symptom amelioration,the level of serum CEA,degree of side effects caused by chemotherapy and physical strength,and count out the difference in the upper aspects between the two groups.
Result:The effective rate of Chinese medicine syndrome evaluation in trail group is 86.67%,the rate of control group is 60.00%.Two groups have Statistically significant differences(p<0.05).It states that the trail group has more prominent advantage than the control group in terms of Relieving clinical symptoms. The KPS before the treatment of two groups'patients have no statistically significant differences. However, the KPS after the treatment of two groups'patients have statistically significant differences(p<0.05).It shows that the trail group has more advantages than the control group in aspect of improving general conditions of patients. CEA has the particular evaluation in diagnosing colorectal cancer.CEA before the treatment of two groups'patients have no statistically significant differences. However, CEA after the treatment of two groups'patients has statistically significant differences. It demonstrate that the trail group also has more advantages than the control group in aspect of reducing CEA value. Recent objective efficiency of curing tumor in the trail group is 33.33%.It is a bit higher than the control group (20.00%).Two groups have no statistically significant differences (p>0.05).
Conclusion:In the treatment of advanced colorectal tumor, Jian Pi Hua Shi Qu Yu Jie Du decoction proved it's function in enhancing the effect of chemotherapy, relieving the toxic and side effects caused by chemotherapy, improving the immune function, ameliorating living quantity and prolonging the life span.
引文
[1]Ferlay J, Bray F, Pisani P, etal. GLOBOCAN 2002:Cancer incidence, mortality and prevalence world wide[C]. IARC cancer Base no.5, version 2.0. Lyon, France:IARC Press,2004.
[2]Jemal A, Murray T, Ward E, etal. Cancer statistics,2005[J]. CA Cancer J Clin,2005,55(1):10-30
[3]万德森.结直肠癌临床研究进展[J].广东医学,2001,22(7)：549-551.
[4]蔡琳,YangB, Parkin D M,等.亚太若干地区恶性肿瘤流行趋势分析[J].肿瘤,2004,24(5)：422-426.
[5]吴苏冬、周冬枝、邓景元等.胃肠道肿瘤脾虚证与血液检测指标的相关性研究[J].陕西中医学院学报,2003,26(2)：46-47.
[6]孙燕,石远凯.临床肿瘤内科手册[M].北京：人民卫生出版社,2009：492.
[7]刘更生.论毒邪[J].山东中医学院学报,1989,13(1)：3.
[8]方志红、李雁、陈昊,等.健脾抗癌方配合化疗治疗晚期大肠癌31例[J].上海中医药杂志,2009,43(3)：29-31.
[9]毛喜莲,黄梅.健脾益气方药减轻肠癌术后化疗不良反应的临床观察[J].山东中医药大学学报,2005,29(2)：128-129.
[10]王维平,连强.中药“消症方”加化疗治疗晚期大肠癌的效果的研究[J],2000,10(6)：559-561.
[11]Abulafi AM, Williams NS. Local recurrence of colorectal cancer; The problem, mechanisms, management and adjuvant therapyt. Br J Surg,1994,81 (1):7.
[12]Simmonds PC. Palliative chemotherapy for advanced colorectal cancer:systematic review and meta-analysis[J]. BMJ,2000,321(7260):531-535.
[13]Souglakos J, Mavroudis D,kakolyris S, et al. Triplet combination with irinotecan plusoxa-liplat in plus continuous-infusion fluorouracial and leucovorin as first-line treatment in metastatic colorectal cancer:amulticenter phaseⅡtrial[J]. J Clin Oncol,2002;20(11):2 651-2657.
[14]HAYDON A. Adjuvant chemotherapy in colon cancer:what is the evidence[J]. InterMed J,20 03,33:119-124.
[15]PETERS M,HALLER D. Therapy for early-stage colorectal cancer[J]. Oncology,1999,13(3):30 7-317.
[16]CUTSEM E V, DICATOM, WILSJ, et al. Adjuvant treatment of colorectal cancer current(expert opinion derived from the Third International Conference perspectives in colorectal cancer) [J]. Eur J Cancer,2002,38:1429-1436.
[17]STARLING N, CHAU I, NORMAN A R, et al.A randomized comparison between six months ofblous fluorouracil/leucovorin and twelve weeks of protracted venous infusion 5-FU as adjuvant treatment in colorectal cancer:an update with 5 years'follow-up[J]. Proc ASCO,2004,2:3523-3524.
[18]郑伟华.口服卡培他滨用于Dukes'C期结直肠癌术后辅助化疗无复发生存优于静脉化疗5-FU/CF方案[J].循证医学,2004,4(3)129-130.
[19]SARISC P, VAARTP JM, RIETBROCK R, etal. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells[J]. Carcinogenesis,1996,17:2763-2769.
[20]De GramontA, FigcerA, SceymourM, et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J].J Clin Oncol,2000,18 (16):2938.
[21]周建凤,陈书长FOLFOX4方案一线治疗晚期大肠癌近期疗效分析[J].癌症进展,2006,4(5)：452.
[22]Andre T,Boni C,Mounedji-Boudiafl L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer[J].N Engl JM ed.2004,350(23):2343.
[23]李玉升.消化道癌辅助化疗新进展[J].癌症进展,2006,4(6)：504.
[24]高凌峰,谭煌英,李园,等.以草酸铂为主方案用于结直肠癌术后辅助化疗的疗效分析[J].癌症进展杂志,2007,5(3)294-297.
[25]赵秀升,雷妍伟,张丽.大肠癌术后腹腔加静脉双路化疗对患者的影响[J].肿瘤研究与临床,2003,15(4)：259.
[26]应江山,曹军宁,印季良,等.伊立替康二线治疗14例晚期结直肠癌[J].中国癌症杂志,2002,12(3)：251-253.
[27]Grand TG, Dattino RM, Efficacy E, et al. Circadian optimization of irinotecan and oxaliplatin in mice with Glasgow osteosarcoma[J]. Br J Cancer,2002,86(6):999-1005.
[28]惠锦林,李红霞,王彬,等.草酸铂和伊立替康、氟尿嘧啶联合方案治疗晚期肠癌[J].中国癌症杂志,2004,14(4)345-347.
[29]宋寄春,谭诗云,陈明锴.半枝莲对人大肠癌细胞增殖抑制及诱导凋亡的作用[J].咸宁学院学报(医学版),2007,21(2)：106-108.
[30]唐广义,殷东风.肠积宁方促进大肠癌细胞株HT-29凋亡及干预相关基因bcl-2及bax表达的实验研究[J].现代肿瘤医学,2007,15(4)：491-493.
[31]雒琳,杨宇飞,李培红,等.中药扶正胶囊和祛邪胶囊减少Ⅱ、Ⅲ期大肠癌术后复发转移的队列研究[J].中国中西医结合杂志,2006,26(8)：677-680.
[32]孟静岩,应森林,李侠,等.芪贞汤对人大肠癌细胞集团移动的影响[J].上海中医药杂志,2006,40(1)：56-57.
[33]杨运高,王程,王学良.红细胞免疫低下与肿瘤转移及活血化瘀方药的调节[J].湖南中医杂志,2004,20(6)：52-54.
[34]王文萍,姜良铎,王垂杰,等.中药复方肠安泰胶囊对大肠癌肺转移模型小鼠肠黏膜T细胞及NK细胞的诱导[J].北京中医药大学学报,2001,24(4)：34-36.
[35]李华山,李华宏,唐宗江,等.肠癌康复汤对大肠癌患者术后免疫功能的影响[J].中国中西医结合杂 志,2000,20(8)：580-582.
[36]Theochariss KouraklisG, MargeliA, et al. Glucocorticoid receptor(GR) immunohistochemical expression is correlated with cell cycle-related molecules in human colon cancerJ].Dig D is Sci,2003,48:1745-1750.
[37]韩春姬.轮叶党参多糖对S180小鼠肉瘤的抑制作用[J].延边大学医学院学报,2000,23(12)：249.
[38]李丽秋,张德慧,马淑霞,等.中草药白花蛇舌草等对实验性大肠癌作用机制的研究[J].中国微生态学杂志,2008,20(3)：224-225.
[39]李敏谊.羧甲基茯苓多糖的免疫调节作用[J].化学通报,1999,(9)：54.
[40]叶敏.薏苡仁水提液对免疫抑制小鼠免疫功能的影响[J].安徽医药,2006,10(10)：727-729.
[41]冯刚,孔庆志,黄冬生,等.薏苡仁注射液对小鼠移植S180肉瘤血管形成抑制的作用[J].肿瘤防治研究,2004,31(4)：229-230.
[42]许建中.黄芪与丹参改善血液高凝状态作用异同的实验研究[J].中成药,1994,(7)：366-368.
[1]孙燕,石远凯.临床肿瘤内科手册[M].北京：人民卫生出版社,2009：491.
[2]O, Connell J Natl Cancer lnst2004,96:1420.
[3]程颖.大肠癌内科治疗的现状[J].实用肿瘤学杂志,2002,16(1)：69.
[4]刘铁龙.健脾解毒中药联合FOLFOX方案治疗结肠癌术后患者的临床研究[J].辽宁中医药大学学报,2009,11(2)105-107.
[5]魏文浩.直肠癌从毒论治[J].河北中医,2000,2(25)：365.
[6]贾小强,邱辉忠.大肠癌辨证分型与肿瘤浸润转移相关性的前瞻性研究[J].中华中医药杂志,2005,2(06)：346.
[7]张代昭.张代昭治癌经验辑要[M].北京：中国医药科技出版社,2001.3.
[8]刘伟胜,徐凯.肿瘤科专病中医临床诊治[M].北京：人民卫生出版社,2005.406.
[9]王小宁,霍介格.中医治疗大肠癌的思路与方法探讨[J].中国中医基础医学杂志,2007,9(4)：681-682.
[10]唐娟,钱钧,黄芳芳.周维顺教授治疗大肠癌的经验[J].云南中医药杂志,2007,28(7)：1-2.
[11]武迎梅,时水治,潘媛,等.扶正解毒化瘀法治疗大肠癌初探[J].北京中医,2006,25(8)：473-475.
[12]陈亚男,吴敏华.大肠癌的诊治新进展[J].中国中医杂志,2006,12(4)：423-425.
[13]蒋益兰,潘博,仇湘中.健脾消癌饮配合化疗治疗大肠癌术后40例总结[J].湖南中医杂志,2001；17：9-10.
[14]张青,赵文硕,于洁,王笑民.益气活血中药联合化疗治疗晚期大肠癌的临床研究[J].中国中医药信息杂志,2006,13：17-18.
[15]梁松岳.肠复方合并化疗治疗大肠癌40例总结[J].湖南中医杂志,2005,21：33-34.
[16]孟静岩,应森林,李侠,等.芪贞汤对人大肠癌细胞集团移动的影响[J].上海中医药杂志,2006,40(1)：56-57.
[17]刘碧清,钱海兵,王毅,等.肠复康对人结肠癌细胞HT-29增殖及浸润转移的影响[J].中国中西医结合消化杂志,2004,12(6)：341-343.
[18]杨运高,王程,王学良.红细胞免疫低下与肿瘤转移及活血化瘀方药的调节[J].湖南中医杂志,2004,20(6)：52-54.
[19]王文海.肠益煎治疗大肠癌术后50例临床观察[J].浙江中西医结合杂志,2000,10(6)：325.
[20]黄智芬,黎汉忠,刘俊波,等.健脾消积汤配合化疗治疗晚期大肠癌疗效观察[J].现代中西医结合杂志,2005,14：1281-1282.
[21]刘静安,张悦红.中西医结合治疗大肠癌术后154例临床观察[J].中草药,2000,31(5)：367.
[22]孙在典,张爱琴.复方四物汤合化疗治疗晚期大肠癌48例[J].浙江中医杂志,2005,6：250.
[23]徐小平,谢云民,王爱华.中医辨证治疗结直肠癌术后化疗后致毒副反应48例临床观察[J].中医药导报,2007,13：31-33.
[24]汤秀红.益气健脾法防治大肠癌化疗后血小板减少的临床观察[J].湖北中医杂志,2009,31(2)：42.
[25]郑玉玲,王新杰.肠达顺灌肠液治疗湿热蕴结型大肠癌的临床研究[J].河南中医,2002,22(1)：12.
[26]杨曦.化疗加中药灌肠治疗晚期大肠癌临床观察[J].中国肛肠病杂志,2006,26(4)：13-15.
[27]李智勇,邓晓军.姑息性切除晚期大肠癌的临床观察[J].中国中西医结合外科杂志,2002,8(5)：343.
[28]张宝南,尤建良.鸦胆子油行TACE术改善大肠癌肝转移生存质量研究[J].辽宁中医杂志,2008,35(1)：84.
[29]金哲秀.针灸两步法治疗大肠癌27例临床分析[J].上海中医药杂志,2003,37：48-49.
[30]穆立新,姜军作.针灸治疗大肠癌术后30例疗效观察[J].大连大学学报,2006,6(1)：35-36.
[31]张宇翔.张东岳教授治疗肛管直肠癌的学术经验.中医药管理杂志,2006,14(2)：56-58.